Progressive multifocal leukoencephalopathy - PDFSEARCH.IO - Document Search Engine

Progressive multifocal leukoencephalopathy
Results: 49

#	Item
21	RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2009-03-31 14:51:38 Efalizumab Progressive multifocal leukoencephalopathy JC virus Psoriasis Genentech Placebo Sepsis Medicine Health Immunosuppressants
22	Possible mechanisms of the disease Add to Reading List Source URL: www.fda.gov Language: English Microbiology Progressive multifocal leukoencephalopathy JC virus Natalizumab Eugene O. Major Rituximab AIDS HIV Sero Health Medicine HIV/AIDS
23	RAPTIVA® [efalizumab] For injection, subcutaneous WARNING: RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) • RAPTIVA increases the risk for PML, a rapidly progressive viral infection of Add to Reading List Source URL: www.fda.gov Language: English Efalizumab Progressive multifocal leukoencephalopathy JC virus Psoriasis Genentech Placebo Sepsis Medicine Health Immunosuppressants
24	Microsoft Word - Rituxan DHCP Letter_FINAL.doc Add to Reading List Source URL: www.fda.gov Language: English Immunosuppressants Rituximab Monoclonal antibodies Biogen Idec JC virus Autoimmune diseases Progressive multifocal leukoencephalopathy Genentech Rheumatoid arthritis Medicine Health Pharmacology
25	721US11REMS00101_v2_HCP Letter_Mech.indd Add to Reading List Source URL: www.fda.gov Language: English Organ transplants Immunosuppressants Progressive multifocal leukoencephalopathy Mycophenolic acid Kidney transplantation Organ transplantation Belatacept Medicine Bristol-Myers Squibb Health
26	Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-02-17 10:44:24 Élan Progressive multifocal leukoencephalopathy Health IDEC Medicine Biology Immunosuppressants Natalizumab Biogen Idec
27	Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-02-17 10:44:23 Élan Progressive multifocal leukoencephalopathy Health Medicine IDEC Biology Immunosuppressants Biogen Idec Natalizumab
28	Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-02-17 10:44:24 Élan Progressive multifocal leukoencephalopathy Health Medicine IDEC Pakistan Muslim League Biology Immunosuppressants Natalizumab Biogen Idec
29	Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-02-17 10:44:23 Élan Progressive multifocal leukoencephalopathy IDEC Health Medicine Biology Immunosuppressants Natalizumab Biogen Idec
30	Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U Add to Reading List Source URL: www.fda.gov Language: English - Date: 2006-02-17 10:44:24 Élan Progressive multifocal leukoencephalopathy Health Medicine IDEC Biology Immunosuppressants Natalizumab Biogen Idec

UPDATE